Challenges for new antibiotic therapy development
A potential for pan-resistant gonorrhea strains has been recognized and there is evidence of rising minimum inhibitory concentration in some isolates for cephalosporins and azithromycin. Whole-genome sequencing of Neisseria gonorrhoeae has identified molecular signatures for reduced susceptibility to current antibiotics, and use of genomic tests to predict antibiotic choice may be one approach to manage emerging antimicrobial resistance. Intramuscular ceftriaxone remains superior to all other antibiotic options for most presentations of gonorrhea. Zoliflodacin is a new antibiotic that is showing efficacy for the treatment of N gonorrhoeae.
Use of this content is subject to our disclaimer